BRAF and colorectal carcinoma: Similarly, the addition of ribavirin enhanced the efficacy of MEK inhibitor cobimetinib against xenografts of BRAF-mutant colorectal carcinoma RKO, even though ribavirin alone had no discernible effect on survival (Figure 4B).